Juno Bio
Provides vaginal microbiome testing for women’s health, supporting analysis of microbial profiles linked to gynecological wellness.
Overview
Juno Bio develops vaginal microbiome testing focused on women’s health, helping characterize microbial profiles relevant to gynecological and reproductive wellness. Its offering targets people and care providers seeking more specialized insight into vaginal health. The company’s differentiation is its focus on a specific, under-served area of microbiome diagnostics rather than broad consumer testing. Ada Ventures and Illumina Accelerator backed a roughly $4M round to help scale its vaginal microbiome testing platform.
Funding History
Ada Ventures and Illumina Accelerator back Juno Bio’s $3.8M round to scale vaginal microbiome testing
Frequently Asked Questions
- How much funding does AI Funding track for Juno Bio?
- AI Funding tracks $4M for Juno Bio across 1 funding round in this database.
- What does Juno Bio do?
- Juno Bio develops vaginal microbiome testing focused on women’s health, helping characterize microbial profiles relevant to gynecological and reproductive wellness. Its offering targets people and care providers seeking more specialized insight into vaginal health. The company’s differentiation is its focus on a specific, under-served area of microbiome diagnostics rather than broad consumer testing. Ada Ventures and Illumina Accelerator backed a roughly $4M round to help scale its vaginal microbiome testing platform.
- Where is Juno Bio headquartered?
- Juno Bio is headquartered in London, United Kingdom.
Related Insights
Compare the leading AI-focused VC firms: Andreessen Horowitz, Sequoia Capital, Thrive Capital, and 7 more. Analysis of 150+ AI deals, investment strategies, sector focus, and portfolio performance.
Track 395+ AI funding rounds—investors, valuations, and deal sizes from pre-seed to IPO. Updated daily so you never miss a round.
An in-depth look at how AI-focused venture capital operates — from fund structure and deal sourcing to due diligence, portfolio management, and exit strategies in the AI era.